A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Etoxeridine (Carbetidine, Atenos) is a 4-phenylpiperidine derivative that is related to the clinically used opioid analgesic drug pethidine (meperidine). Etoxeridine was developed in the 1950s and investigated for use in surgical anesthesia, however it was never commercialized and is not currently used in medicine. As with other opioids which were not in clinical use during the drafting of the Controlled Substances Act, it is categorized as a Schedule I narcotic.
In molecular biology, ATP10 protein (mitochondrial ATPase complex subunit ATP10) is an ATP synthase assembly factor. It is essential for the assembly of the mitochondrial F1-F0 complex. A yeast nuclear gene (ATP10) encodes a product that is essential for the assembly of a functional mitochondrial ATPase complex. Mutations in ATP10 induce a loss of rutamycin sensitivity in the mitochondrial ATPase, but do not affect the respiratory enzymes. ATP10 has a molecular weight of 30,293 Da and its primary structure is not related to any known subunit of the yeast or mammalian mitochondrial ATPase complexes. ATP10 is associated with the mitochondrial membrane. It is suggested that the ATP10 product is not a subunit of the ATPase complex but rather a protein required for the assembly of the F0 sector of the complex.
Todd's other television appearances include a recurring role on Boston Public and guest appearances on Law & Order, Homicide: Life on the Street, Hercules: The Legendary Journeys, Xena: Warrior Princess as Cecrops, The X-Files, Smallville, Psych, Angel, 24, Charmed, Stargate SG-1, Andromeda, Criminal Minds, 21 Jump Street, and Chuck. Todd is one of the few actors to have portrayed two different speaking roles on 24. He was initially cast as Detective Michael Norris in season three and four years later as General Benjamin Juma in both 24: Redemption and season 7. He also played a major role in the Babylon 5 TV film A Call to Arms. He portrayed several characters in the Star Trek universe: Worf's brother Kurn in Star Trek: The Next Generation and Star Trek: Deep Space Nine, an adult Jake Sisko in the episode "The Visitor" in Star Trek: Deep Space Nine, and an Alpha Hirogen in the episode "Prey" in Star Trek: Voyager. In 2017, Todd returned to the world of Star Trek as General Rodek in the MMORPG game Star Trek Online. Todd also provided the voices of the Decepticon Dreadwing on Transformers: Prime, and Icon in Young Justice. In 2015, Todd was cast as the disguised voice of Zoom (portrayed by Teddy Sears when undisguised) in the second season of The Flash. Todd would later reprise his role in the fifth season episodes "What's Past Is Prologue" and "Godspeed" (though the latter featured archive audio of Todd instead) and returned to the role one last time for the series finale, "A New World, Part Four".
Fisher formulate a zinc insulin mixture at Connaught Laboratories in Toronto and license it to Novo 1936 Hagedorn discovers that adding protamine to insulin prolongs the duration of action of insulin 1946 Nordisk formulates Isophane porcine insulin aka Neutral Protamine Hagedorn or NPH insulin 1946 Nordisk crystallizes a protamine and insulin mixture 1950 Nordisk markets NPH insulin 1953 Novo formulates Lente porcine and bovine insulins by adding zinc for longer lasting insulin 1955 Frederick Sanger determines the amino acid sequence of insulin 1965 Synthesized by total synthesis by Wang Yinglai, Chen-Lu Tsou, et al. 1969 Dorothy Crowfoot Hodgkin characterizes and describes the crystal structure of insulin by X-ray crystallography 1973 Purified monocomponent (MC) insulin is introduced 1973 The US officially "standardized" insulin sold for human use in the US to U-100 (100 units per milliliter). Prior to that, insulin was sold in different strengths, including U-80 (80 units per milliliter) and U-40 formulations (40 units per milliliter), so the effort to "standardize" the potency aimed to reduce dosage errors and ease doctors' job of prescribing insulin for people. Other countries also followed suit.
Sources: en.wikipedia.org
Analyzing proteins proves to be more difficult than analyzing nucleic acid sequences. While there are only 4 nucleotides that make up DNA, there are at least 20 different amino acids that can make up a protein. Additionally, there is currently no known high throughput technology to make copies of a single protein. Numerous methods are available to study proteins, sets of proteins, or the whole proteome. In fact, proteins are often studied indirectly, e.g. using computational methods and analyses of genomes. Only a few examples are given below.
==== United Kingdom ==== The UK National Health Service (NHS) recommends that people at risk of vitamin D deficiency, breast-fed babies, formula-fed babies taking no more than 500 ml of infant formula a day, and children aged 6 months to 4 years, should take daily vitamin D supplements throughout the year to ensure sufficient intake. This includes people with limited skin synthesis of vitamin D, who are not often outdoors, are frail, housebound, living in a care home, or usually wearing clothes that cover up most of the skin, or with dark skin, such as having an African, African-Caribbean or south Asian background. Other people may be able to make adequate vitamin D from sunlight exposure from April to September. The NHS and Public Health England recommend that everyone, including those who are pregnant and breastfeeding, consider taking a daily supplement containing 10 μg (400 IU) of vitamin D during autumn and winter because of inadequate sunlight for vitamin D synthesis.
In the United States in 1999, there were 14,420 non-fatal traumatic amputations according to the American Statistical Association. Of these, 4,435 occurred as a result of traffic and transportation accidents and 9,985 were due to labor accidents. Of all traumatic amputations, the distribution percentage is 30.75% for traffic accidents and 69.24% for labor accidents. The United States Bureau of Labor Statistics reported 6,200 cases of work-related amputations in 2018. The most common causes of amputations were machinery (58% cases), crush injuries from parts or material (15%), and other tools/instruments/equipment such hand tools (7%). A study found that in 2010, 22.8% of patients undergoing amputation of a lower extremity in the United States were readmitted to the hospital within 30 days. In 2017, an estimated 57.7 million people globally were living with existing traumatic limb injuries. Of these 57.7 million, the leading causes of amputation "were falls (36.2%), road injuries (15.7%), other transportation injuries (11.2%), and mechanical forces (10.4%)." On 2 August 2023, an investigation by The Wall Street Journal found that Ukrainian medical amputations in the war came to between 20,000 and 50,000 including both military and civilians. In comparison, during World War One 41,000 British and 67,000 Germans needed amputations. In 2025, Israel's attacks on the Gaza Strip during the Gaza war caused Gaza to have the highest number of child amputees per capita in the world.
=== Flavin-dependent ene-reductases === Flavin-dependent ERs perform their reactions using the cofactor flavin mononucleotide (FMN) that is non-covalently bonded to the enzyme and their catalytic mechanism is now well understood. In the natural cycle, the cofactor (FMN) is first reduced by NAD(P)H, then the reduced FMNH2 reduces the substrate by Michael-type hydride transfer to the β-carbon atom. In the end the protonation of the resulting anion occurs from the opposite face of the (C=C) bond through a tyrosine moiety or solvent. The overall reaction is an anti-trans-hydrogenation. This catalytic mechanism can also be regenerated from the natural nicotinamide cofactor with a substrate-coupled regeneration or the use of synthetic reductants and electrochemical or photochemical regeneration. The most predominant family of flavin-dependent ERs is the Old Yellow Enzyme (OYE) family of oxidoreductases (EC 1.6.99.1).The first OYE was discovered in baker's yeast (Saccharomyces cerevisiae) in 1933, and its name derives from the color it assumes when concentrated, which is due to the flavin cofactor. They catalyze the reduction of α,β-unsaturated compounds, with a high specificity for activating groups containing aldehydes, ketones, or nitro groups. Conversely, carboxylic acids and their derivatives such as esters and nitriles, are less activated and are considered as "borderline substrates".
=== Vital statistics === Births from January–September 2016 = 19,138 Births from January–September 2017 = 19,086 Deaths from January–September 2016 = 25,153 Deaths from January–September 2017 = 25,832 Natural growth from January–September 2016 = -6,015 Natural growth from January–September 2017 = -6,746
Sources: en.wikipedia.org
This is a list of countries by coffee production, based on data from the Food and Agriculture Organization (FAO) for 2023. This data covers the production of green coffee beans, the primary ingredient in the production of processed coffee. Roasting and packaging of ground coffee often takes place after it has been exported from the producing nation; see the separate list of countries by coffee exports. Coffee is a cash crop in many areas, with the amount produced for export significantly in excess of local demand. Several of these countries maintain substantial supply-chain relations with the world's largest coffeehouse chains and enterprises. Often these coffeehouse chains pay a premium above market price in order to alleviate fair trade and sustainable farming concerns. Developing countries that participate in the coffee market wield considerable influence on global coffee economics.
It can also be produced by oxidising the ephedrine analogue 4-methylephedrine using potassium permanganate dissolved in sulfuric acid. Because 4-methylephedrine can be obtained in a specific enantiomeric form, mephedrone consisting of only one enantiomer can be produced. The danger associated with this method is it may cause manganese poisoning if the product is not correctly purified.
=== Physical and atomic === Darmstadtium is expected to be a solid under normal conditions and to crystallize in the body-centered cubic structure, unlike its lighter congeners which crystallize in the face-centered cubic structure, because it is expected to have different electron charge densities from them. It should be a very heavy metal with a density of around 26–27 g/cm3. In comparison, the densest known element that has had its density measured, osmium, has a density of only 22.61 g/cm3. The outer electron configuration of darmstadtium is calculated to be 6d8 7s2, which obeys the Aufbau principle and does not follow platinum's outer electron configuration of 5d9 6s1. This is due to the relativistic stabilization of the 7s2 electron pair over the whole seventh period, so that none of the elements from 104 to 112 are expected to have electron configurations violating the Aufbau principle. The atomic radius of darmstadtium is expected to be around 132 pm.
Russian television presenter and journalist Ksenia Sobchak publicly criticized Peters, describing his looksmaxxing content as harmful, arguing his online image "reflects increasingly extreme views and unhealthy attitudes toward self-image." Turning Point USA spokesman Andrew Kolvet sees Peters' looksmaxxing message as part of a "giant red warning sign" reflecting "a growing mentorship vacuum among young men searching for guidance." Peters has described himself as apolitical and stated in 2026 that he "would never want to be associated with politics", which he has described as "jester", a looksmaxxing term for a "foolish waste of time". Lauren Smith wrote for Spiked that he was "seen as a player in the Very Online right" but that he was "best understood not as a right-wing thought leader" due to "only offer[ing] a parody of masculinity", while Joanna Williams wrote for The Telegraph that he had "been embraced by America's Very Online Right" and that he, Fuentes, and Tate "make the overlap between politics and appearance explicit". For the Miami New Times, Alex DeLuca wrote that he was "associated with [the] 'manosphere' and far-right extremism".
=== Specificity === The specific activities of sv-LAAOs with various L-amino acids have been explored. Many studies show that a number of sv-LAAOs exhibit a preference for hydrophobic L-amino acids as substrates. For example, results have indicated that most sv-LAAOs demonstrate relatively high specificities toward hydrophobic amino acids such as L-Met, L-Leu, and L-Ile in addition to aromatic amino acids such as L-Phe and L-Trp.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.